Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies

Zheng Pang; Renee Raudonis; Bernard R. Glick; Tong Jun Lin; Zhenyu Cheng

doi:10.1016/j.biotechadv.2018.11.013

Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies

Zheng Pang, Renee Raudonis, Bernard R. Glick, Tong Jun Lin, Zhenyu Cheng

Research output: Contribution to journal › Review article › peer-review

1509 Citations (Scopus)

Abstract

Pseudomonas aeruginosa is an opportunistic pathogen that is a leading cause of morbidity and mortality in cystic fibrosis patients and immunocompromised individuals. Eradication of P. aeruginosa has become increasingly difficult due to its remarkable capacity to resist antibiotics. Strains of Pseudomonas aeruginosa are known to utilize their high levels of intrinsic and acquired resistance mechanisms to counter most antibiotics. In addition, adaptive antibiotic resistance of P. aeruginosa is a recently characterized mechanism, which includes biofilm-mediated resistance and formation of multidrug-tolerant persister cells, and is responsible for recalcitrance and relapse of infections. The discovery and development of alternative therapeutic strategies that present novel avenues against P. aeruginosa infections are increasingly demanded and gaining more and more attention. Although mostly at the preclinical stages, many recent studies have reported several innovative therapeutic technologies that have demonstrated pronounced effectiveness in fighting against drug-resistant P. aeruginosa strains. This review highlights the mechanisms of antibiotic resistance in P. aeruginosa and discusses the current state of some novel therapeutic approaches for treatment of P. aeruginosa infections that can be further explored in clinical practice.

Original language	English
Pages (from-to)	177-192
Number of pages	16
Journal	Biotechnology Advances
Volume	37
Issue number	1
DOIs	https://doi.org/10.1016/j.biotechadv.2018.11.013
Publication status	Published - Jan 1 2019

Bibliographical note

Funding Information:
We thank Janie Zhang for assistance in making the figures. The work in Tong-Jun Lin's lab have been supported by the Discovery Grant from Natural Sciences and Engineering Research Council, Canada (NSERC) of Canada and Canadian Institute of Heath Research (CIHR). The research in Zhenyu Cheng's lab has been supported by Cystic Fibrosis Canada and a Discovery Grant from NSERC.

Funding Information:
We thank Janie Zhang for assistance in making the figures. The work in Tong-Jun Lin’s lab have been supported by the Discovery Grant from Natural Sciences and Engineering Research Council , Canada (NSERC) of Canada and Canadian Institute of Heath Research (CIHR). The research in Zhenyu Cheng’s lab has been supported by Cystic Fibrosis Canada and a Discovery Grant from NSERC.

Publisher Copyright:
© 2018 The Author(s)

ASJC Scopus Subject Areas

Biotechnology
Bioengineering
Applied Microbiology and Biotechnology

Access to Document

10.1016/j.biotechadv.2018.11.013

Cite this

@article{d2481c6dd98642ab878e8a25ec01e95a,

title = "Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies",

abstract = "Pseudomonas aeruginosa is an opportunistic pathogen that is a leading cause of morbidity and mortality in cystic fibrosis patients and immunocompromised individuals. Eradication of P. aeruginosa has become increasingly difficult due to its remarkable capacity to resist antibiotics. Strains of Pseudomonas aeruginosa are known to utilize their high levels of intrinsic and acquired resistance mechanisms to counter most antibiotics. In addition, adaptive antibiotic resistance of P. aeruginosa is a recently characterized mechanism, which includes biofilm-mediated resistance and formation of multidrug-tolerant persister cells, and is responsible for recalcitrance and relapse of infections. The discovery and development of alternative therapeutic strategies that present novel avenues against P. aeruginosa infections are increasingly demanded and gaining more and more attention. Although mostly at the preclinical stages, many recent studies have reported several innovative therapeutic technologies that have demonstrated pronounced effectiveness in fighting against drug-resistant P. aeruginosa strains. This review highlights the mechanisms of antibiotic resistance in P. aeruginosa and discusses the current state of some novel therapeutic approaches for treatment of P. aeruginosa infections that can be further explored in clinical practice.",

author = "Zheng Pang and Renee Raudonis and Glick, {Bernard R.} and Lin, {Tong Jun} and Zhenyu Cheng",

note = "Funding Information: We thank Janie Zhang for assistance in making the figures. The work in Tong-Jun Lin's lab have been supported by the Discovery Grant from Natural Sciences and Engineering Research Council, Canada (NSERC) of Canada and Canadian Institute of Heath Research (CIHR). The research in Zhenyu Cheng's lab has been supported by Cystic Fibrosis Canada and a Discovery Grant from NSERC. Funding Information: We thank Janie Zhang for assistance in making the figures. The work in Tong-Jun Lin{\textquoteright}s lab have been supported by the Discovery Grant from Natural Sciences and Engineering Research Council , Canada (NSERC) of Canada and Canadian Institute of Heath Research (CIHR). The research in Zhenyu Cheng{\textquoteright}s lab has been supported by Cystic Fibrosis Canada and a Discovery Grant from NSERC. Publisher Copyright: {\textcopyright} 2018 The Author(s)",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/j.biotechadv.2018.11.013",

language = "English",

volume = "37",

pages = "177--192",

journal = "Biotechnology Advances",

issn = "0734-9750",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Antibiotic resistance in Pseudomonas aeruginosa

T2 - mechanisms and alternative therapeutic strategies

AU - Pang, Zheng

AU - Raudonis, Renee

AU - Glick, Bernard R.

AU - Lin, Tong Jun

AU - Cheng, Zhenyu

N1 - Funding Information: We thank Janie Zhang for assistance in making the figures. The work in Tong-Jun Lin's lab have been supported by the Discovery Grant from Natural Sciences and Engineering Research Council, Canada (NSERC) of Canada and Canadian Institute of Heath Research (CIHR). The research in Zhenyu Cheng's lab has been supported by Cystic Fibrosis Canada and a Discovery Grant from NSERC. Funding Information: We thank Janie Zhang for assistance in making the figures. The work in Tong-Jun Lin’s lab have been supported by the Discovery Grant from Natural Sciences and Engineering Research Council , Canada (NSERC) of Canada and Canadian Institute of Heath Research (CIHR). The research in Zhenyu Cheng’s lab has been supported by Cystic Fibrosis Canada and a Discovery Grant from NSERC. Publisher Copyright: © 2018 The Author(s)

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pseudomonas aeruginosa is an opportunistic pathogen that is a leading cause of morbidity and mortality in cystic fibrosis patients and immunocompromised individuals. Eradication of P. aeruginosa has become increasingly difficult due to its remarkable capacity to resist antibiotics. Strains of Pseudomonas aeruginosa are known to utilize their high levels of intrinsic and acquired resistance mechanisms to counter most antibiotics. In addition, adaptive antibiotic resistance of P. aeruginosa is a recently characterized mechanism, which includes biofilm-mediated resistance and formation of multidrug-tolerant persister cells, and is responsible for recalcitrance and relapse of infections. The discovery and development of alternative therapeutic strategies that present novel avenues against P. aeruginosa infections are increasingly demanded and gaining more and more attention. Although mostly at the preclinical stages, many recent studies have reported several innovative therapeutic technologies that have demonstrated pronounced effectiveness in fighting against drug-resistant P. aeruginosa strains. This review highlights the mechanisms of antibiotic resistance in P. aeruginosa and discusses the current state of some novel therapeutic approaches for treatment of P. aeruginosa infections that can be further explored in clinical practice.

AB - Pseudomonas aeruginosa is an opportunistic pathogen that is a leading cause of morbidity and mortality in cystic fibrosis patients and immunocompromised individuals. Eradication of P. aeruginosa has become increasingly difficult due to its remarkable capacity to resist antibiotics. Strains of Pseudomonas aeruginosa are known to utilize their high levels of intrinsic and acquired resistance mechanisms to counter most antibiotics. In addition, adaptive antibiotic resistance of P. aeruginosa is a recently characterized mechanism, which includes biofilm-mediated resistance and formation of multidrug-tolerant persister cells, and is responsible for recalcitrance and relapse of infections. The discovery and development of alternative therapeutic strategies that present novel avenues against P. aeruginosa infections are increasingly demanded and gaining more and more attention. Although mostly at the preclinical stages, many recent studies have reported several innovative therapeutic technologies that have demonstrated pronounced effectiveness in fighting against drug-resistant P. aeruginosa strains. This review highlights the mechanisms of antibiotic resistance in P. aeruginosa and discusses the current state of some novel therapeutic approaches for treatment of P. aeruginosa infections that can be further explored in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85057518466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057518466&partnerID=8YFLogxK

U2 - 10.1016/j.biotechadv.2018.11.013

DO - 10.1016/j.biotechadv.2018.11.013

M3 - Review article

C2 - 30500353

AN - SCOPUS:85057518466

SN - 0734-9750

VL - 37

SP - 177

EP - 192

JO - Biotechnology Advances

JF - Biotechnology Advances

IS - 1

ER -

Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this